PBI4 Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA): Real-World Experience in the US

Abstract

Authors

S.M. Helfgott J. Radtchenko N. Soloman K. Huston J.A. Singh C. Edgerton

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×